Thursday 03 July, 2014, Christie Hospital, Manchester
1-day course: Molecular Mechanisms of Targeted Cancer Treatments
Level: Advanced/expert (Designed for doctors – from medical students to consultants – and senior oncology staff with a biological background. Ideal for junior doctors considering a future in oncology)
Description: This course covers a wide range of licensed and experimental cancer treatments, explaining their mechanism of action at a molecular and cellular level. It also contains information on mechanisms of drug resistance to targeted agents and discusses the future of personalised cancer medicine.
To book, contact: education.events@christie.nhs.uk
Programme
Targeted cancer treatments: the current landscape
- Where have we got to?
- Hallmarks of cancer cells – choose your target
The main classes of current targeted treatments:
- Monoclonal antibody (mAb) technology
- Small molecule kinase inhibitors
Targeting cell communication pathways
- Inhibitors of EGF-R and HER2
- PI3K,AKT & mTOR inhibitors
- B-RAF & MEK inhibitors
More enzyme inhibitors
- VEGFR/angiogenesis inhibitors
- PARP inhibitors
- ALK inhibitors
Practical exercise
Novel innovations to combat cancer
- Epigenetic modifiers
- HSP90 inhibitors
- Immunotherapy
- Hedgehog pathway inhibitors
Molecular and cellular mechanisms of drug resistance
- Intrinsic and acquired drug resistance
- Molecular mechanisms of drug resistance
- The influence of intratumoural heterogeneity and the tumour microenvironment
Biomarkers and the personalisation of cancer treatment
- Introduction to biomarkers
- The use of biomarkers to select patients for trials and treatments for patients
- The future of personalised cancer medicine